We're taking a closer look at Ionis Pharmaceuticals today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -11.4% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
-
Ionis Pharmaceuticals has moved 11.1% over the last year compared to 22.6% for the S&P 500 -- a difference of -11.5%
-
IONS has an average analyst rating of buy and is -31.36% away from its mean target price of $62.4 per share
-
Its trailing 12 month earnings per share (EPS) is $-2.52
-
Ionis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -17.0 while the S&P 500 average is 28.21
-
Its forward earnings per share (EPS) is $-3.59 and its forward P/E ratio is -11.9
-
IONS has a Price to Earnings Growth (PEG) ratio of -0.37, which shows the company is fairly valued compared to its earnings.
-
The company has a Price to Book (P/B) ratio of 23.72 in contrast to the S&P 500's average ratio of 4.71
-
Ionis Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 27.61 and an average P/B of 3.69
-
Ionis Pharmaceuticals has on average reported free cash flows of $50.37 Million over the last four years, during which time they have grown by an an average of -21.5%
